Rubraca™ (rucaparib) – New Orphan Drug Approval
December 19, 2016 – The FDA announced the approval of Clovis Oncology’s Rubraca (rucaparib), indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies.
Top